Wednesday, August 26, 2026

Corporate Strategy

2 articles

Coupa Acquires Rossum, Launches Two AI Products, and Hosts Conference on the Same Day

Coupa Acquires Rossum, Launches Two AI Products, and Hosts Conference on the Same Day

Coupa executed a three-part platform blitz on May 12, 2026: acquiring AI document intelligence company Rossum, launching AI products Catalyst and Compose, and holding a major conference simultaneously. The coordinated move signals aggressive competitive repositioning in enterprise spend management. Rivals Basware, Tipalti, Medius, and Tungsten face pressure to respond within 60-90 days.

LM Salvado
American Express's Cloud Analytics Overhaul to Hit 100% Completion in 2027, Reshaping Competitive Edge

American Express's Cloud Analytics Overhaul to Hit 100% Completion in 2027, Reshaping Competitive Edge

American Express is on track to fully migrate to its third-generation cloud-based data and analytics platform by 2027, a move that has already delivered a 90% reduction in processing time for key marketing and fraud operations. The upgrade underpins the company's ability to deploy generative AI at scale and deepen personalization across its premium card portfolio. Backed by $5 billion in annual technology spend, the platform migration is central to AmEx's strategy to widen its operational moat a

ViaNews Editorial Team (Markets)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com